lilly retatrutide New GLP-1 obesity drug, retatrutide, shows added benefits Eli Lilly 2023: Crossover appeal

Since then, Wegovy has become one of the most popular prescription weight loss drugs, leading to a supply shortage towards the end of 2022

ZL: Writing review & editing

Much of the focus is on obtaining a new indication for obesity for already FDA-approved diabetes medications such as Tirzepatide (Mounjaro) from Eli Lilly, which was recently approved for obesity under the brand name Zepbound

Based on current clinical evidence, Mounjaro (tirzepatide) is generally the best tolerated of the available options, with lower rates of nausea compared to semaglutide at equivalent weight loss doses

Eli Lilly is awaiting an FDA decision for a new indication for Mounjaro to reduce the risk of a major adverse cardiovascular event (MACE) in patients with type 2 diabetes mellitus (T2DM)